News Breaks |
|
|
| January 28, 2013 |
| 06:30 EDT |  | BIIB | Biogen reports Q4 EPS $1.40, consensus $1.46
Reports Q4 revenue $1.42B, consensus $1.39B |
|
|
News For BIIB From The Last 14 Days Check below for free stories on BIIB the last two weeks. |
|
|
| May 24, 2013 |
| 07:20 EDT |  | BIIB | Celgene, Gilead, and Biogen could go much higher, says Bernstein
 Subscribe for More Information |
|
| May 23, 2013 |
| 08:04 EDT |  | BIIB | Biogen appoints Spyros Artavanis-Tsakonas as Chief Scientific Officer
Subscribe for More Information |
|
| May 21, 2013 |
| 07:24 EDT |  | BIIB | Global Health Care to host a conference
Subscribe for More Information |
|
| 05:44 EDT | | BIIB | Biogen submits application to FDA for approval of Plegridy in RMS
Subscribe for More Information |
|
| May 20, 2013 |
| 15:57 EDT | | BIIB | Biogen IMS numbers should not be adjusted down at ISI Group
ISI Group confirmed with Biogen that Tecfidera is not captured by IMS and numbers should not be adjusted downward to reflect free drugs dispensed. |
|
| 07:39 EDT | | BIIB | Biogen weekly MS drug scripts up 26.5%, says Citigroup
Citigroup says weekly scripts for Biogen's multiple sclerosis drug Tecfidera were up 26.5% to 1,621. Citi says the launch of Tecfidera is on track to beat Q2 estimates by a wide margin and it keeps a Buy rating on shares of Biogen. |
|
| May 16, 2013 |
| 07:29 EDT | | BIIB | Leerink to host a bus tour
Boston Biopharma Bus Tour travels throughout Boston on May 16-17. |
|
| May 14, 2013 |
| 15:09 EDT | | BIIB | Biogen has a conference call hosted by JPMorgan
JPMorgan Analysts Meacham and Kasimov host a conference call with CEO George Scangos and CFO Paul Clancy on May 17 at 10 am. |
|
| May 13, 2013 |
| 11:12 EDT | | BIIB | Biogen MS drug scripts grew 38% week-over-week, says Leerink
Subscribe for More Information |
|
| 07:34 EDT | | BIIB | Biogen says FDA accepts BLA for Eloctate
Subscribe for More Information |
| |
| May 10, 2013 |
| 08:00 EDT | | BIIB | Biogen should be bought on weakness before Q2 Tecfidera data, says Stifel
Stifel recommends buying Biogen on any weakness before the company reports Q2 Tecfidera sales data. The firm thinks that any continued strength in Tecfidera prescription data will cause analysts to revise their estimates higher, and it keeps a Buy rating on the shares. |
|
|
|
|
|
